Biotech Values

[DewDiligence]

This physician survey is bullish for ABT, PFE/AMGN, JNJ/MRK, and (paradoxically) MNTA:

http://finance.yahoo.com/news/rheumatologists-gastroenterologists-reluctant-prescribe-biosimilars-130000415.html

BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed gastroenterologists and rheumatologists in the United States and Europe have a low or medium-low likelihood of prescribing a biosimilar for an indication in which it has not been clinically tested.

The survey is bullish for ABT, PFE/AMGN, and JNJ/MRK because they sell the three leading biologics for RA (Humira, Enbrel, and Remicade, respectively). It is bullish for MNTA because an interchangeable FoB in the US for one of the above drugs will not have to be prescribed in order to be used.